Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01820572 · ClinicalTrials.gov registry record · Phase 3
A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 446
- Enrollment target
NCT01820572 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 446 participants.
The verdict
NCT01820572, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 446 participants
- Enrollment target
Study Summary
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
Interventions
- DRUG Tacrolimus
- DRUG Cyclosporine
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2013-03-27 |
| Est. Completion | 2019-10-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01820572
The ClinicalTrials.gov registry entry for NCT01820572 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT01820572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01820572 about?
NCT01820572 is a clinical study titled "A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based". The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
What is the current status of trial NCT01820572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 446 participants. The study started on 2013-03-27. Estimated completion is 2019-10-24.
What interventions are being tested in trial NCT01820572?
The interventions under investigation include: Tacrolimus (DRUG), Cyclosporine (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT01820572?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.